Dupilumab, a biologic drug known by the brand name Dupixent, is currently a subject of interest regarding potential biosimilar entries. The FDA's Purple Book lists approved biological products, including biosimilars and interchangeables [1]. As of now, no biosimilar for dupilumab has been approved by the FDA [2].
When Might a Dupilumab Biosimilar Become Available?
The availability of a biosimilar for dupilumab is contingent on several factors, primarily patent expiry and regulatory approval. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate potential timelines for generic or biosimilar competition [3]. However, specific patent expiration dates and subsequent market entry dates for biosimilars are not always predictable due to potential legal challenges and the complex nature of patent law.
What Does the FDA Purple Book Track?
The FDA's Purple Book, officially titled "Lists of Licensed FDA-Approved Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations," serves as a reference for approved biologics. It includes information on biosimilars and interchangeable biosimilars once they receive FDA approval [1].
How Are Biosimilars Developed?
Biosimilars are biological products that are highly similar to an already approved biological medicine (the reference product). They must demonstrate no clinically meaningful differences in terms of safety, purity, and potency. The development process involves extensive analytical studies, animal studies, and clinical studies to confirm this similarity [4].
What Are the Potential Impacts of a Dupilumab Biosimilar?
The introduction of biosimilars for biologic drugs can lead to increased competition, potentially resulting in lower drug prices. This can improve patient access to treatments like dupilumab, which is used for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis [5].
Who Manufactures Dupilumab?
Dupilumab (Dupixent) is manufactured by Sanofi and Regeneron Pharmaceuticals [6].
What Are the Regulatory Requirements for Biosimilars?
To be approved, a biosimilar must meet the same standards of safety, efficacy, and quality as the reference product. The FDA's regulatory pathway for biosimilars aims to ensure that these products are safe and effective for their intended use [4].